Observational studyMedicine2015
Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma: A Case-Control Study.
Observational study in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A comprehensive evaluation for polymorphisms inBioscience reports · 2018Pooled it
- An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic stroke.Journal of thrombosis and thrombolysis · 2016Trial
- An rs4705342 T>C polymorphism in the promoter of miR-143/145 is associated with a decreased risk of ischemic stroke.Scientific reports · 2016Trial
- The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.Cell biology and toxicology · 2024Review
- Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach.European thyroid journal · 2022Article
- MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.Frontiers in oncology · 2021Review
- A genetic variant rs13293512 in the promoter of let-7 is associated with an increased risk of breast cancer in Chinese women.Bioscience reports · 2019Article
- Lethal-7-related polymorphisms are associated with susceptibility to and prognosis of gastric cancer.World journal of gastroenterology · 2019Observational
- Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.Oncology letters · 2018Article
- A new panel of SNPs to assess thyroid carcinoma risk: a pilot study in a Brazilian admixture population.BMC medical genetics · 2017Article
- Genetic polymorphisms of non-coding RNAs associated with increased head and neck cancer susceptibility: a systematic review and meta-analysis.Oncotarget · 2017Article
- Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.European thyroid journal · 2017Review
- The association of six single nucleotide polymorphisms and their haplotypes in CDH13 with T2DM in a Han Chinese population.Medicine · 2017Observational
- A polymorphism rs4705341 in the flanking region of miR-143/145 predicts risk and prognosis of colorectal cancer.Oncotarget · 2016Article
- A functional variant rs353292 in the flanking region of miR-143/145 contributes to the risk of colorectal cancer.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the association between 2 polymorphisms (ie, rs10877887 and rs13293512) in the promoter regions of let-7 and the risk of papillary thyroid carcinoma (PTC).A case-control study of 618 PTC patients and 562 controls was conducted. The rs10877887 polymorphism was genotyped by using polymerase chain reaction-restriction fragment length polymorphism and the rs13293512 polymorphism was genotyped by using a TaqMan Genotyping Assay. The results were confirmed by DNA sequencing.The rs10877887 polymorphism had reduced risks of PTC in heterozygous comparison, dominant model, and overdominant model (TC vs TT: adjusted odds ratio [OR] = 0.73, 95% confidence interval [95% CI] = 0.58-0.94, P = 0.01; TC/CC vs TT: adjusted OR = 0.79, 95% CI = 0.63-1.00, P = 0.047; TC vs TT/CC: adjusted OR = 0.73, 95% CI = 0.57-0.92, P = 0.007, respectively). Stratified analyses showed that PTC patients carrying the rs10877887 CC genotype were more likely to have multiple tumors (adjusted OR = 1.71, 95% CI = 1.03-2.86, P = 0.04), and PTC patients carrying the rs13293512 TC + CC or CC were more likely to develop N0 status (TC/CC vs TT: adjusted OR = 0.64, 95% CI = 0.43-0.94, P = 0.02; CC vs TC/TT: adjusted OR = 0.50, 95% CI = 0.33-0.77, P = 0.001, respectively).Our study suggests that the rs10877887 polymorphism may be associated with the risk of PTC and the rs13293512 polymorphism may correlate to lymph node metastasis in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.